Mark L. Baum is a prominent figure in the pharmaceutical industry, known for his strategic investments and leadership roles in various companies. As of August 2024, his estimated net worth stands at an impressive $86 million. This wealth primarily stems from his significant holdings in Harrow Inc., Eton Pharmaceuticals Inc., and Ideal Power Inc.
Baum serves as the Chief Executive Officer of Harrow Inc., where he holds approximately 2,137,525 shares valued at over $83 million. His role in the company has been pivotal, especially in navigating the complexities of the pharmaceutical landscape. Additionally, he is a director at Eton Pharmaceuticals Inc., owning about 794,745 shares worth over $3 million. His investment in Ideal Power Inc. is relatively modest, with 2,906 shares valued at around $23,510.
Mark L. Baum’s financial activities are closely monitored through SEC filings, which provide insights into his trading patterns and stock holdings. The following sections will delve deeper into his investments, trading history, and overall performance in the stock market.
Investment Portfolio Overview
| Company | Stock Symbol | Shares Owned | Value | Weighting |
|---|---|---|---|---|
| Harrow Inc. | HROW | 2,137,525 | $83 Million | 96.27% |
| Eton Pharmaceuticals Inc. | ETON | 794,745 | $3 Million | 3.71% |
| Ideal Power Inc. | IPWR | 2,906 | $23,510 | 0.03% |
Insider Trading Activity
Mark L. Baum’s trading history reveals a consistent pattern of acquiring shares rather than selling them. Over the past five years, he has executed four transactions in Harrow Inc., all of which were purchases. The most recent transaction occurred on March 22, 2024, when he acquired 9,000 shares for approximately $104,310. This trend indicates Baum’s confidence in the future performance of Harrow Inc.
In contrast, Baum has not engaged in any transactions involving Eton Pharmaceuticals or Ideal Power in the past five years, suggesting a long-term investment strategy in these companies. His last purchase of Eton shares was in November 2018, while his last transaction with Ideal Power dates back to March 2017.
Performance Metrics
Baum’s investment strategy appears to be effective, as evidenced by the average return of stocks he has purchased. According to GuruFocus, the average return of stocks bought by Baum within three months is 17.94%. This performance outpaces the S&P 500 benchmark in five out of seven transactions, highlighting his ability to make profitable investment decisions.
Recent Trading Trends
In the past 18 months, Baum has made three insider transactions in Harrow Inc., resulting in a net purchase of 22,300 shares. This activity aligns with a broader trend among insiders at Harrow, who collectively bought 257,300 shares during the same period, indicating strong confidence in the company’s prospects.
Conclusion
Mark L. Baum’s estimated net worth of $86 million as of 2024 reflects his successful career in the pharmaceutical industry and his strategic investment choices. His significant holdings in Harrow Inc. and other companies demonstrate his commitment to long-term growth and value creation. As he continues to navigate the complexities of the market, Baum’s performance will be closely watched by investors and analysts alike.
FAQs
What is Mark L. Baum’s net worth as of 2024?
Mark L. Baum’s estimated net worth is $86 million as of August 2024.
What companies does Mark L. Baum have investments in?
Baum has significant investments in Harrow Inc., Eton Pharmaceuticals Inc., and Ideal Power Inc.
How many shares of Harrow Inc. does Mark L. Baum own?
He owns approximately 2,137,525 shares of Harrow Inc., valued at over $83 million.
What is Mark L. Baum’s trading strategy?
Baum primarily focuses on acquiring shares rather than selling them, indicating a long-term investment strategy.
How has Mark L. Baum’s investment performance compared to the market?
His investments have outperformed the S&P 500 benchmark in five out of seven transactions, with an average return of 17.94% within three months of purchase.